David Boyer, MD, on Promising Efficacy of Suprachoroidal Gene Therapy in nAMD
The senior partner at Retina Vitreous Associates Medical Group discussed efficacy and safety data from the phase 2 AAVIATE trial.
David Boyer, MD, on Potential Advantages of Suprachoroidal Gene Therapy for Neovascular AMD
The senior partner at Retina Vitreous Associates Medical Group discussed new findings from the AAVIATE study of RGX-314.